GSK GSK

Name: GSK Crucible Score
Creator: Kaladin Capital Intelligence

UnknownUnknownN/A📅 Scored April 20, 2026

Price at analysis: $58.35

Crucible Score

66.2

B-

Quality × Value Composite

KQI — Quality

67.2

B-

Fundamental Quality Index

KVI — Value

65.1

B-

Valuation Attractiveness Index

Crucible Verdict — GSK

GlaxoSmithKline earns a solid B- grade driven by strong management effectiveness under Emma Walmsley's nine-year tenure and consistent earnings performance, but poor diversification scores and mediocre growth prospects limit upside potential. GSK trades at a modest 8% discount to fair value, offering reasonable entry for income-focused investors seeking pharmaceutical exposure with limited growth expectations.

— Kal, Kaladin Capital Intelligence

◆ KQI Quality Dimensions

Financial Quality

70.6

Growth Profile⚠

54.7

Moat Durability

70.3

Management Effectiveness⚠

73.6

Diversification & Resilience⚠

48.0

Market Position

68.0

Weakest dimension: Diversification & Resilience (48.0)

◆ KVI Value Dimensions

DCF Margin of Safety

58.7

FCF Yield & Cash Returns

64.2

Relative Valuation

95.0

Growth-Adjusted Value

33.3

Historical Valuation

76.9

Macro Context

87.7

◆ DCF Valuation Scenarios

Bear Case

$42.18

Base Case

$62.74

Bull Case

$89.53

Price at Analysis

$58.35

Scenario	Fair Value	Rev CAGR (5yr)	Terminal Margin	WACC
🔴 Bear	$42.18	2.0%	18.0%	6.3%
🟢 Base	$62.74	4.0%	22.0%	6.1%
🟢 Bull	$89.53	6.0%	26.0%	5.8%

Key Assumptions: WACC calculated using CAPM with 4.32% risk-free rate, 0.35 beta, and 5.5% ERP yielding ~6.2% cost of equity, blended with after-tax cost of debt (~3.5%) at ~40% debt weighting. Revenue growth anchored to historical ~5% CAGR with GSK's pipeline optionality (Shingrix, HIV, oncology) driving upside; bear case reflects patent cliff risks and pricing pressure compressing margins toward 18%. Tax rate set at 14% reflecting GSK's historical effective rate excluding one-time items, and capex intensity at 5.5% of revenue consistent with trailing averages.

◆ Financial Snapshot

Profitability

Gross Margin72.5%

Operating Margin21.9%

Net Margin17.5%

ROIC12.9%

ROE-178.5%

Balance Sheet

Balance SheetCR: 0.82

Cash ConversionFCF/EPS: 0.88x

Capital IntensityCapex/Rev: 4.1%

Altman Z-Score2.28 (Grey)

Piotroski F-Score7/9 (Good)

Growth

Revenue CAGR7.2% CAGR

Earnings CAGR9.4% CAGR

Growth ConsistencyCV: 4.62

Segment BreadthInsufficient segments

Quarterly TrendRev↑, Margin∆, Exp↓

Earnings CredibilityTends to Beat

◆ Analyst Consensus & Leadership

Leadership & Governance

CEOEmma Walmsley · 9 years

Insider ActivityBuying

Capital AllocationROIC 12.9% vs WACC 3.1%

Earnings Beat Rate90% (18/20)

◆ Related Companies in Our Universe

Other Unknown companies scored by the Crucible:

ADBE81.8A-NICE80.7A-DECK79.9A-INTU79.9A-EXEL78.3A-MTCH78.2A-TTD78.0B+

Methodology All Scores Crucible Briefs Performance @KaladinCI

Analysis conducted April 20, 2026 based on most recent SEC filings. Updated quarterly, after new SEC filings.

Point-in-time fundamental analysis. Not investment advice. Scores reflect company quality and valuation at time of analysis and may not reflect current market conditions.